Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Al Collard who wrote (1269)	2/23/2003 12:43:52 AM
From: Cal Gary	Respond to of 1321

QLT halts tariquidar study enrolment for safety review QLT Inc QLT Shares issued 68,229,615 Feb 20 close $13.66 Fri 21 Feb 2003 News Release Ms. Therese Hayes reports QLT TEMPORARILY SUSPENDS NEW PATIENT ACCRUAL IN PHASE III STU ... Enrolment of additional patients in QLT's continuing phase III studies of tariquidar in non-small cell lung cancer patients is being suspended for approximately three months pending the completion of the planned interim safety and efficacy analysis by an independent data and safety monitoring committee (DSMC). The DSMC has recommended that accrual to the trials be temporarily halted until all patients currently enrolled have been followed for a minimum of three months and that the patients should continue to be treated and followed according to the protocol. The committee also stated that all data should remain blinded and that the intention of this halt in accrual is to permit, for those patients already entered, acquisition and review of additional data on safety and efficacy. The DSMC concluded that the recommendations above "provided the best opportunity for these trials to remain intact and to serve, in their entirety as pivotal registration trials for regulatory purposes." The DSMC is an independent panel of experts who are not participating in the studies. The primary responsibility of the DSMC is to oversee the studies and safeguard the interests of current and future participants in these trials. The DSMC has not reviewed any efficacy data for the trials. Accrual in the two phase III studies had already reached the threshold number of patients required for the three-month interim analysis. The DSMC felt that a review of the patients enrolled to date would be sufficient "to permit an assessment of differences in response rates between the two arms of the trial, and to provide information on short to mid term differences in survival" and to make an initial assessment of therapeutic benefit to potential risk. About tariquidar Enrolment began in June, 2002, for the two phase III clinical trials using tariquidar as an adjunctive treatment in combination with first-line chemotherapy for non-small cell lung cancer (NSCLC) patients. Approximately 1,000 patients were to be enrolled in two randomized, multicentred, placebo-controlled trials using tariquidar in combination with two of the most commonly used chemotherapy regimens (paclitaxel plus carboplatin or vinorelbine alone). The trials, being conducted at roughly 100 centres located throughout North America and Europe, are designed to demonstrate the ability of tariquidar to enhance the efficacy of chemotherapy agents. This occurs by preventing or overcoming resistance due to overexpression of P-glycoprotein (P-gp), a membrane protein that pumps chemotherapeutic agents out of cancer cells. Overall survival is the primary end-point in both trials. The U.S. Food and Drug Administration (FDA) has granted fast track review status to tariquidar for the treatment of multidrug resistance in first-line treatment of NSCLC patients. Upon successful completion of the phase III program, it is anticipated that QLT will file for approval of tariquidar in North America for use in combination with first-line chemotherapy in advanced NSCLC in 2005. NSCLC is the first of several indications for which tariquidar will be investigated. QLT is also continuing its phase II trial with tariquidar in patients with refractory breast cancer at the University of Texas MD Anderson Cancer Center. Tariquidar was in-licensed from Xenova Group PLC for the development and marketing rights in North America in August, 2001. Conference call information QLT will hold an analyst and institutional investor conference call to discuss this item on Friday, Feb. 21 at 8:30 a.m. ET (5:30 a.m. PT). The call will be broadcast live via the Internet on the company's Web site. A replay of the call will be available via the Internet and also via telephone at (416) 695-5800, access code 1381104. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 2003 Canjex Publishing Ltd. stockwatch.com